ClinicalTrials.gg
RecruitingNCT05816850FIL_FOLL-BIOUpdated Dec 29, 2025

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

An observational study in Follicular Lymphoma, sponsored by Fondazione Italiana Linfomi - ETS. Recruiting at 26 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Fondazione Italiana Linfomi - ETS · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
654
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Lymphoma, Follicular by Fondazione Italiana Linfomi - ETS — 2 open to participants now, 6 under way, 3 of them phase 3. Lymphoma, Follicular · Fondazione Italiana Linfomi - ETS.

Started
2023
with 1 other
Observational
3 of 14
1 open now
Registered
11th of 14
by date

Among the 14 studies in Lymphoma, Follicular by Fondazione Italiana Linfomi - ETS, this one is one of 2 that started in 2023, is one of 3 observational ones, and was the 11th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

2 of the 14 studies in Lymphoma, Follicular by Fondazione Italiana Linfomi - ETS are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lymphoma, Follicular by Fondazione Italiana Linfomi - ETS, or all of them as a file.
02

Study summary

This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.

Read the detailed description

Current standard first-line treatment for advanced follicular lymphoma (FL) is still represented by chemoimmunotherapy combinations, with CHOP/CVP or bendamustine (B) as the main regimens with no standard criteria to prefer one over another.

EZH2 mutations have been associated with longer progression-free survival (PFS) in patients treated with CHOP/CVP regimens, but not with Bendamustine (independently from the type of anti-CD20 therapy received).

The FIL_FOLL12 trial (NCT02063685), a large phase III trial (with a pre-planned biological material sampling) enrolling 807 advanced FL patients treated with front-line R-CHOP or bendamustine-rituximab (BR), appears an ideal platform to validate the predictive value of EZH2 and its applicability to the clinical practice.

The aim of this study is to provide to clinicians a useful and practical biomarker to guide the choice of the most effective chemotherapy backbone (in addition to anti-CD20 immunotherapy) for first line treatment of patients with advanced FL (e.g. R-CHOP for EZH2 aberrated vs BR for EZH2 wild type patients).

Moreover, to implement an Italian network of laboratories able to provide these translational outputs within a rapid turnaround time.

Finally, taking advantage of the already collected BM and PB samples, several novel biomarkers of FL heterogeneity will be investigated, in particular: EZH2 protein expression in tumor samples, alternative molecular markers for minimal residual disease (MRD), clonal hematopoiesis of indeterminate potential (CHIP), pharmacogenomics and constitutional genomics as well as microbiome profiles.

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Lymphoma
  • Follicular
  • Immunochemotherapy
  • FL
  • Aberration
  • Mutation
  • EZH2
  • CHOP
  • Bendamustine
  • Biological
  • Rituximab
  • Biomarker
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient affected by advanced Follicular Lymphoma treated with immunochemotherapy in the FIL_FOLL12 trial

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient enrolled in the FIL_FOLL12 trial (documented by the signature of the study );
  • Availability of biological samples: bone marrow aspirate, peripheral blood and/or FFPE diagnostic sample (nodal or extranodal);

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
654 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients enrolled

    Patient affected by advanced Follicular Lymphoma treated with immunochemotherapy in the FIL\_FOLL12 trial

    Diagnostic Test: EZH2 mutations/CNAs by droplet digital PCR (ddPCR) · Diagnostic Test: EZH2-derived gene expression signature by RNA-Seq

Interventions

  • Diagnostic testEZH2 mutations/CNAs by droplet digital PCR (ddPCR)

    Test of EZH2 mutations/CNAs by droplet digital PCR (ddPCR) in peripheral blood and in unsorted bone marrow aspirate samples at enrolment

  • Diagnostic testEZH2-derived gene expression signature by RNA-Seq

    Test of EZH2-derived gene expression signature by RNA-Seq in a subset of diagnostic FFPE samples

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Time between the treatment start and the first documentation of recurrence, progression or death from any cause

    Time frame: From treatment start up to 43 months

Secondary outcomes

  1. Response rate

    Response rate (complete metabolic response/minimal residual disease (MRD) negativity) at the end of induction.

    Time frame: From treatment start to 7 months (R-Bendamustine) or from treatment start to 5,6 months (R-CHOP)

  2. Concordance between EZH2 gene mutations/gains and EZH2-related gene expression signature

    Concordance between EZH2 gene mutations/gains and EZH2-related gene expression signature

    Time frame: Before treatment start

07

Study locations

19 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 18, 2023
StartActual
Sep 19, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05816850
Lead sponsor
Fondazione Italiana Linfomi - ETS
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Sep 19, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Uffici Studi FIL
Contact
startup@filinf.it
+390131033153
Uffici Studi FIL
Contact
gestionestudi@filinf.it
+390599769913
Simone Ferrero, MD
principal investigator · SC Ematologia U - AOU Città della Salute e della Scienza di Torino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion